Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
– Submitted IND for PBGM01 Phase 1/2 trial; currently on FDA clinical hold pending additional review of proposed ICM delivery […]
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
TEL AVIV, Israel, Aug. 13, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second […]
Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi […]
Nano Dimension Reports 2020 Second Quarter Financial Results
Prolonged Covid-19 status leads to emphasis on product enhancementsConference call to be held today at 9:00 a.m. EDTBOCA RATON, Fla., […]
Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights
– Upsized IPO in June 2020 raised $244.4 million in gross proceeds –Bay Street News
Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update
Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 millionNEW YORK and SAN DIEGO, Aug. 13, […]
MTBC Reports Second Quarter 2020 Results, Reaffirms Guidance
Reaffirms Full-Year Revenue and Adjusted EBITDA Guidance with Implied Year-over-year Increases of Over 63% and 48%, RespectivelySOMERSET, N.J., Aug. 13, […]
RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase […]
HOOKIPA Pharma Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing […]
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple MyelomaPBCAR0191 and […]
